ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual property. Eighty-nine patents are held in over eighty countries.

The ATLATL Center for Innovation & Research is a global innovation research and development center located in the heart of multiple prestigious science parks in China, creating a new life sciences ecosystem by partnering with entrepreneurs, investors, pharmaceutical companies, and service companies.

Eric Rhodes, CEO at ERS Genomics, made the following statement: "With an ever-expanding portfolio of CRISPR/Cas9 technology patents, including more recent grants in China, ERS is pleased and honored to be partnering with ATLATL to make CRISPR/Cas9 more accessible worldwide. China is a leader in the use of CRISPR technology across a broad variety of applications and we look forward to working with ATLATL to bring forward these exciting commercial opportunities."

CEO of ATLATL, PC Zhu, explained how ATLATL will facilitate CRISPR/Cas9 technology's utilization to contribute to global biotech industry: "CRISPR/Cas9 technology has revolutionized the life science industry across various fields. We are very excited to help in advancing the gene-editing landscape by licensing ERS' CRISPR/Cas9 patent to the broader scientific community. We are honored to help more firms and researchers commercialize CRISPR/Cas9 technology with officially validated gene-editing licenses, enhancing global innovation with broader applications of this cutting-edge technology."

Financial details of the agreement are not disclosed.